Credit: Getty Images. The combination antibiotic consists of aztreonam, a monobactam β-lactam and avibactam, a broad-spectrum β-lactamase inhibitor. The investigational antibiotic combination ...

Please provide your email address to receive an email when new articles are posted on . Aztreonam-avibactam was well tolerated and comparable in efficacy to meropenem. Pfizer plans to start the ...

Review the side-effects of Aztreonam as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to ATM-AVI (aztreonam and avibactam; Allergan) for the treatment ...

Aztreonam (Aztreo (1000 mg)) is monobactam antibiotic, prescribed for serious infections caused by susceptible gram negative bacteria like urinary tract infection, lower respiratory tract infection.

Am J Health Syst Pharm. 2012;69(2):107-115. Kristen Zeitler, Pharm.D., is Postgraduate Year 1 Pharmacy Practice Resident, Hospital of the University of Pennsylvania, Philadelphia; at the time of ...

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEOTM (aztreonam and avibactam), as the first ...

DUBLIN--(BUSINESS WIRE)--The "Aztreonam Injection Market Insights 2020 - Analysis and Forecasts for the Global and Chinese Markets to 2025, by Manufacturers, Regions, Technology, Product Type" report ...

EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by ...